The BNT162b2 mRNA COVID-19 vaccine showed high efficacy in clinical trials but observational data from populations not included in trials are needed. We describe immunogenicity 21 days post-dose 1 among 514 Israeli healthcare workers by age, ethnicity, sex and prior COVID-19 infection. Immunogenicity was similar by ethnicity and sex but decreased with age. Those with prior infection had antibody titres one magnitude order higher than naïve individuals regardless of the presence of detectable IgG antibodies pre-vaccination.
All Keywords
【저자키워드】 COVID-19, Vaccine, immunogenicity, Israel, 【초록키워드】 Efficacy, COVID-19 vaccine, clinical trial, Trial, Infection, Sex, Population, IgG antibody, COVID-19 infection, age, Observational data, BNT162b2 mRNA, Antibody titre, pre-vaccination, detectable, magnitude, Israeli healthcare worker, naïve individual, 【제목키워드】 Infection, Sex, healthcare, Impact, age, BNT162b2 mRNA, single dose, Evidence,
【저자키워드】 COVID-19, Vaccine, immunogenicity, Israel, 【초록키워드】 Efficacy, COVID-19 vaccine, clinical trial, Trial, Infection, Sex, Population, IgG antibody, COVID-19 infection, age, Observational data, BNT162b2 mRNA, Antibody titre, pre-vaccination, detectable, magnitude, Israeli healthcare worker, naïve individual, 【제목키워드】 Infection, Sex, healthcare, Impact, age, BNT162b2 mRNA, single dose, Evidence,